Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

NCT03139032 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate the study

Conditions

Inflammatory Bowel Diseases
Skin Extra-intestinal Manifestations

Interventions

DRUG: APD334

Sponsor

Arena Pharmaceuticals